Evidence map›Paper›PMID 41439917›Full record

ArticleBiomimetics (Basel, Switzerland)2025

A Fluid Dynamics-Model System for Advancing Tissue Engineering and Cancer Research Studies: Biological Assessment of the Innovative BioAxFlow Dynamic Culture Bioreactor.

Giulia Gramigna, Federica Liguori, Ludovica Filippini, Maurizio Mastantuono, Michele Pistillo, Margherita Scamarcio, Alessia Mengoni, Antonella Lisi, Giuseppe Falvo D'Urso Labate, Mario Ledda

Abstract read
In one paragraph

Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Giulia GramignaInstitute of Translational Pharmacology (CNR-IFT), National Research Council, Via Fosso del Cavaliere 100, 00133 Roma, Italy.
Federica LiguoriCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.ORCID 0009-0000-6014-0476
Ludovica FilippiniCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.ORCID 0000-0003-3526-0331
Maurizio MastantuonoCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.
Michele PistilloCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.
Margherita ScamarcioCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.
Alessia MengoniInstitute of Translational Pharmacology (CNR-IFT), National Research Council, Via Fosso del Cavaliere 100, 00133 Roma, Italy.
Antonella LisiInstitute of Translational Pharmacology (CNR-IFT), National Research Council, Via Fosso del Cavaliere 100, 00133 Roma, Italy.ORCID 0000-0002-5465-9500
Giuseppe Falvo D'Urso LabateCellex S.r.L, Piazzale delle Belle Arti 2, 00196 Roma, Italy.
Mario LeddaInstitute of Translational Pharmacology (CNR-IFT), National Research Council, Via Fosso del Cavaliere 100, 00133 Roma, Italy.ORCID 0000-0002-0349-8938

Funding

European Commission project-HORIZON-MSCA-2021-SE-01 OSTEONET - GA n. 101086329Ministero dell'università e della ricerca MUR DSB.AD006.371.010 / Invecchiamento attivo e in salute (FOE 2022) IFTMinistero dell'università e della ricerca MUR PNRR project "Rome Technopole Innovation EcosystemRegione Lazio 3DCREATORProgramma FESR Lazio 2021-2027 "Riposizionamento Competitivo" CUP "B53D23034400001.
6 · The paper itself

Abstract

In this study, an innovative bioreactor, named BioAxFlow, particularly suitable for tissue engineering applications, is tested. Unlike traditional bioreactors, it does not rely on mechanical components to agitate the culture medium, but on the unique fluid-dynamics behaviour induced by the geometry of the culture chamber, which ensures continuous movement of the medium, promoting the constant exposure of the cells to nutrients and growth factors. Using the human osteosarcoma cell line SAOS-2, the bioreactor's ability to enhance cell adhesion and proliferation on polylactic acid (PLA) scaffolds, mimicking bone matrix architecture, is investigated. Cells cultured in the bioreactor showed significant improvement in cell growth and adhesion, compared to static cultures, and a more homogeneous cell distribution upon the scaffold surfaces, which is crucial for the development of functional tissue constructs. The bioreactor also preserves the osteogenic potential of SAOS-2 cells as assessed by the expression of key osteogenic markers. Additionally, it retains the tumorigenic characteristics of SAOS-2 cells, including the expression of pro-angiogenic factors and apoptosis-related genes. These results indicate that the BioAxFlow bioreactor could be an effective platform for tissue engineering and cancer research, offering a promising tool for both regenerative medicine applications and drug testing.

Indexed as

3D cell culturebioreactorsin vitro tumor modelosteosarcoma cell linetissue engineering

Identifiers

PMID41439917
PMCPMC12731094

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.